vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Enpro Inc. (NPO). Click either name above to swap in a different company.
Enpro Inc. is the larger business by last-quarter revenue ($295.4M vs $196.0M, roughly 1.5× Axsome Therapeutics, Inc.). Enpro Inc. runs the higher net margin — -10.8% vs -14.6%, a 3.7% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 14.3%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 7.1%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Enpro is a US-based industrial technology company that designs and manufactures products and materials for technology-intensive sectors. The company serves industries such as semiconductors, aerospace, power generation, heavy-duty trucking, agricultural machinery, chemical processing, pulp and paper, and life sciences from 61 primary manufacturing facilities located in 12 countries, worldwide. It is organized under three segments: Sealing Technologies, Advanced Surface Technologies, and Engin...
AXSM vs NPO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $295.4M |
| Net Profit | $-28.6M | $-32.0M |
| Gross Margin | — | 42.1% |
| Operating Margin | -13.8% | 11.2% |
| Net Margin | -14.6% | -10.8% |
| Revenue YoY | 65.0% | 14.3% |
| Net Profit YoY | 61.9% | -330.2% |
| EPS (diluted) | $-0.55 | $-1.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $295.4M | ||
| Q3 25 | $171.0M | $286.6M | ||
| Q2 25 | $150.0M | $288.1M | ||
| Q1 25 | $121.5M | $273.2M | ||
| Q4 24 | $118.8M | $258.4M | ||
| Q3 24 | $104.8M | $260.9M | ||
| Q2 24 | $87.2M | $271.9M | ||
| Q1 24 | $75.0M | $257.5M |
| Q4 25 | $-28.6M | $-32.0M | ||
| Q3 25 | $-47.2M | $21.6M | ||
| Q2 25 | $-48.0M | $26.4M | ||
| Q1 25 | $-59.4M | $24.5M | ||
| Q4 24 | $-74.9M | $13.9M | ||
| Q3 24 | $-64.6M | $19.8M | ||
| Q2 24 | $-79.3M | $26.7M | ||
| Q1 24 | $-68.4M | $12.5M |
| Q4 25 | — | 42.1% | ||
| Q3 25 | — | 41.9% | ||
| Q2 25 | — | 43.3% | ||
| Q1 25 | — | 43.3% | ||
| Q4 24 | — | 42.3% | ||
| Q3 24 | — | 42.3% | ||
| Q2 24 | — | 43.8% | ||
| Q1 24 | — | 41.2% |
| Q4 25 | -13.8% | 11.2% | ||
| Q3 25 | -27.0% | 14.3% | ||
| Q2 25 | -24.5% | 15.9% | ||
| Q1 25 | -46.9% | 15.3% | ||
| Q4 24 | -61.1% | 12.5% | ||
| Q3 24 | -59.8% | 13.1% | ||
| Q2 24 | -89.5% | 17.7% | ||
| Q1 24 | -89.7% | 10.9% |
| Q4 25 | -14.6% | -10.8% | ||
| Q3 25 | -27.6% | 7.5% | ||
| Q2 25 | -32.0% | 9.2% | ||
| Q1 25 | -48.9% | 9.0% | ||
| Q4 24 | -63.1% | 5.4% | ||
| Q3 24 | -61.7% | 7.6% | ||
| Q2 24 | -91.0% | 9.8% | ||
| Q1 24 | -91.1% | 4.9% |
| Q4 25 | $-0.55 | $-1.50 | ||
| Q3 25 | $-0.94 | $1.01 | ||
| Q2 25 | $-0.97 | $1.25 | ||
| Q1 25 | $-1.22 | $1.15 | ||
| Q4 24 | $-1.54 | $0.65 | ||
| Q3 24 | $-1.34 | $0.94 | ||
| Q2 24 | $-1.67 | $1.27 | ||
| Q1 24 | $-1.44 | $0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $114.7M |
| Total DebtLower is stronger | — | $655.3M |
| Stockholders' EquityBook value | $88.3M | $1.5B |
| Total Assets | $689.8M | $2.7B |
| Debt / EquityLower = less leverage | — | 0.42× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $114.7M | ||
| Q3 25 | $325.3M | $132.9M | ||
| Q2 25 | $303.0M | $107.1M | ||
| Q1 25 | $300.9M | $240.3M | ||
| Q4 24 | $315.4M | $236.3M | ||
| Q3 24 | $327.3M | $206.9M | ||
| Q2 24 | $315.7M | $175.9M | ||
| Q1 24 | $331.4M | $163.9M |
| Q4 25 | — | $655.3M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $640.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $644.9M |
| Q4 25 | $88.3M | $1.5B | ||
| Q3 25 | $73.7M | $1.5B | ||
| Q2 25 | $73.1M | $1.5B | ||
| Q1 25 | $53.2M | $1.5B | ||
| Q4 24 | $57.0M | $1.4B | ||
| Q3 24 | $92.9M | $1.5B | ||
| Q2 24 | $102.9M | $1.4B | ||
| Q1 24 | $144.0M | $1.4B |
| Q4 25 | $689.8M | $2.7B | ||
| Q3 25 | $669.3M | $2.4B | ||
| Q2 25 | $639.8M | $2.4B | ||
| Q1 25 | $596.7M | $2.5B | ||
| Q4 24 | $568.5M | $2.5B | ||
| Q3 24 | $561.5M | $2.5B | ||
| Q2 24 | $548.2M | $2.5B | ||
| Q1 24 | $545.7M | $2.5B |
| Q4 25 | — | 0.42× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.45× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.46× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | — |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | 4.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $1.0M | $65.3M | ||
| Q2 25 | $-32.4M | $52.2M | ||
| Q1 25 | $-43.4M | $21.0M | ||
| Q4 24 | $-26.2M | $59.4M | ||
| Q3 24 | $-18.6M | $54.0M | ||
| Q2 24 | $-30.1M | $43.2M | ||
| Q1 24 | $-53.5M | $6.3M |
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | $53.4M | ||
| Q2 25 | $-32.4M | $42.3M | ||
| Q1 25 | $-43.7M | $13.0M | ||
| Q4 24 | $-26.2M | $49.1M | ||
| Q3 24 | $-18.7M | $48.3M | ||
| Q2 24 | $-30.2M | $38.3M | ||
| Q1 24 | $-53.6M | $-1.9M |
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | 18.6% | ||
| Q2 25 | -21.6% | 14.7% | ||
| Q1 25 | -36.0% | 4.8% | ||
| Q4 24 | -22.1% | 19.0% | ||
| Q3 24 | -17.9% | 18.5% | ||
| Q2 24 | -34.6% | 14.1% | ||
| Q1 24 | -71.4% | -0.7% |
| Q4 25 | 0.0% | 4.1% | ||
| Q3 25 | 0.0% | 4.2% | ||
| Q2 25 | 0.0% | 3.4% | ||
| Q1 25 | 0.3% | 2.9% | ||
| Q4 24 | 0.0% | 4.0% | ||
| Q3 24 | 0.1% | 2.2% | ||
| Q2 24 | 0.1% | 1.8% | ||
| Q1 24 | 0.1% | 3.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 3.02× | ||
| Q2 25 | — | 1.98× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 4.27× | ||
| Q3 24 | — | 2.73× | ||
| Q2 24 | — | 1.62× | ||
| Q1 24 | — | 0.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
NPO
| Sealing Technologies Segment | $187.0M | 63% |
| General Industrial | $71.3M | 24% |
| Power Generation | $19.9M | 7% |
| Oiland Gas Market | $15.0M | 5% |
| Semiconductors | $2.2M | 1% |
